DEA’s suspension of McKesson Corporation Retraction

Posted in Latest News on January 19, 2017.

The previous post, regarding the DEA’s suspension of McKesson Corporation’s sales of controlled substances from distribution in Florida, was found to be confusing. This suspension will impact one distribution center in Florida and impacts only the handling of hydromorphone. The Florida Department of Health and Division of Medical Quality Assurance apologizes for any confusion that may have resulted from that message. For specific details about McKesson’s agreement with the DEA, please contact the DEA. For questions about the potential impact of the sanctions in Florida, please contact the DOH’s Medical Quality Assurance.



More Latest News

Hurricane Michael and Medications
October 17, 2018

Please click here for Frequently Asked Questions and more information about filling prescriptions after the hurricane. Continue reading


Class III Institutional Pharmacies
October 17, 2018

Beginning on October 19, 2018, the Board of Pharmacy will be issuing permits for this new class of pharmacy. Continue reading